Moderna CEO Stéphane Bancel has stressed that the company is not just a COVID-19 vaccine maker. Now, Cambridge, Massachusetts–based Moderna (NSDQ:MRNA) has announced that its mRNA-based cytomegalovirus (CMV) vaccine candidate is entering a Phase 3 pivotal registration study. “Moderna has been focusing on a vaccine against CMV for a number of years,” said Lori Panther,…